Kidney-type glutaminase is a biomarker for the diagnosis and prognosis of hepatocellular carcinoma: a prospective study

• Published in: BMC cancer Vol. 23; no. 1; pp. 1 - 1081
• Main Authors: Zhang, Laizhu, Su, Ke, Liu, Qi, Li, Binghua, Wang, Ye, Cheng, Chunxiao, Li, Yunzheng, Xu, Chun, Chen, Jun, Wu, Hongyan, Zhu, Mengxia, Mai, Xiaoli, Cao, Yajuan, Peng, Jin, Yue, Yang, Ding, Yitao, Yu, Decai
• Format: Journal Article
• Language: English
• Published: London BioMed Central Ltd 09-11-2023; BioMed Central; BMC
• Subjects: Ablation; Antigens; Biomarker; Biomarkers; Cancer therapies; Chemotherapy; Clinical trials; Diagnosis; Glutaminase; Glycoproteins; Heparan sulfate proteoglycans; Hepatitis; Hepatocellular carcinoma; Hepatoma; Immunohistochemistry; Immunotherapy; Kidneys; Liver cancer; Liver diseases; Magnetic resonance imaging; Medical prognosis; Metabolism; Microvasculature; Nomograms; Prognosis; Statistical analysis; Surgery; α-Fetoprotein; China; Beijing China
• ISSN: 1471-2407; 1471-2407
• DOI: 10.1186/s12885-023-11601-y

Purpose The pathological diagnosis and prognosis prediction of hepatocellular carcinoma (HCC) is challenging due to the lack of specific biomarkers. This study aimed to validate the diagnostic and prognostic efficiency of Kidney-type glutaminase (GLS1) for HCC in prospective cohorts with a large sample size. Methods A total of 1140 HCC patients were enrolled in our prospective clinical trials. Control cases included 114 nontumour tissues. The registered clinical trial (ChiCTR-DDT-14,005,102, chictr.org.cn) was referred to for the exact protocol. GLS1 immunohistochemistry was performed on the whole tumour section. The diagnostic and prognostic performances of GLS1 was evaluated by the receiver operating characteristic curve and Cox regression model. Results The sensitivity, specificity, positive predictive value, negative predictive value, Youden index, and area under the curve of GLS1 for the diagnosis of HCC were 0.746, 0.842, 0.979, 0.249, 0.588, and 0.814, respectively, which could be increased to 0.846, 0.886, 0.987,0.366, 0.732, and 0.921 when combined with glypican 3 (GPC3) and alpha-fetoprotein (AFP), indicating better diagnostic performance. Further, we developed a nomogram with GPC3 and GLS1 for identifying HCC which showed good discrimination and calibration. GLS1 expression was also related with age, T stage, TNM stage, Edmondson-Steiner grade, microvascular invasion, Ki67, VEGFR2, GPC3, and AFP expression in HCC. GLS1 expression was negatively correlated with disease-free survival (P < 0.001) probability of patients with HCC. Conclusions It was validated that GLS1 was a sensitive and specific biomarker for pathological diagnosis of HCC and had prognostic value, thus having practical value for clinical application. Keywords: Biomarker, Diagnosis, Glutaminase, Hepatocellular carcinoma, Prognosis